ProfileGDS5678 / 1437889_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 96% 97% 96% 98% 96% 97% 97% 96% 96% 95% 96% 96% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.427497
GSM967853U87-EV human glioblastoma xenograft - Control 29.0346196
GSM967854U87-EV human glioblastoma xenograft - Control 39.4385297
GSM967855U87-EV human glioblastoma xenograft - Control 48.8969296
GSM967856U87-EV human glioblastoma xenograft - Control 59.9261398
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.5282896
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.0767697
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.0719897
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.9737996
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.7750296
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.2822595
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.8418896
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.003896
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.6114395